Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 2/20 | 0.52 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.49 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.46 |
| ▸ | FAAH | O00519 | 2/20 | 0.46 |
| ▸ | PPARG | P37231 | 2/20 | 0.45 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1506724 | 1.00 | FFAR1 (0.52) | FFAR1FFAR4PTPN1GPR84FAAH | |
| SCHEMBL1506742 | 1.00 | FFAR1 (0.52) | FFAR1FFAR4PTPN1GPR84FAAH | |
| SCHEMBL1506722 | 1.00 | FFAR1 (0.52) | FFAR1FFAR4PTPN1GPR84FAAH | |
| SCHEMBL29033645 | 0.94 | FFAR1 (0.57) | FFAR1FFAR4PTPN1GPR84FAAH | |
| SCHEMBL31197061 | 0.93 | FFAR1 (0.43) | FFAR1FFAR4PTPN1FAAHPPARG | |
| SCHEMBL25332133 | 0.92 | PTPN1 (0.55) | FFAR1FFAR4PTPN1PPARGGPR132 | |
| SCHEMBL1129947 | 0.92 | FFAR1 (0.59) | FFAR1FFAR4PTPN1GPR84FAAH | |
| SCHEMBL2258628 | 0.92 | FFAR1 (0.59) | FFAR1FFAR4PTPN1GPR84FAAH | |
| SCHEMBL8335201 | 0.92 | PTPN1 (0.55) | FFAR1FFAR4PTPN1PPARGGPR132 | |
| SCHEMBL2901186 | 0.92 | FFAR1 (0.59) | FFAR1FFAR4PTPN1GPR84FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4468884-A1 | LYMPH-RELEASING COMPOSITIONS OF FATTY ACIDS AND USES THEREOF FOR LYMPHATIC INCORPORATION AND SYSTEMIC DISEASE TREATMENT | Amarin Pharmaceuticals Ireland Limited (IE) | 2024-12-04 | — | — | EP | claimed |
| WO-2023146984-A1 | LYMPH-RELEASING COMPOSITIONS OF FATTY ACIDS AND USES THEREOF FOR LYMPHATIC INCORPORATION AND SYSTEMIC DISEASE TREATMENT | AMARIN PHARMACEUTICALS IRELAND LIMITED (IE) | 2023-08-03 | — | — | WO | claimed |
| US-20190078042-A1 | BARLEY FOR PRODUCTION OF FLAVOR-STABLE BEVERAGE | CARLSBERG A/S (DK) | 2019-03-14 | — | — | US | claimed |
| US-20150218498-A1 | BARLEY FOR PRODUCTION OF FLAVOR-STABLE BEVERAGE | CARLSBERG A/S (DK) | 2015-08-06 | — | — | US | claimed |
| JP-4805249-B2 | — | — | 2011-11-02 | — | — | JP | claimed |
| US-20110195151-A1 | BARLEY FOR PRODUCTION OF FLAVOR-STABLE BEVERAGE | CARLSBERG A/S (DK) | 2011-08-11 | — | — | US | claimed |
| CN-1981041-B | Barley for production of flavor-stable beverage | CARLSBERG AS | 2011-03-23 | — | — | CN | claimed |
| EP-2290089-A2 | Barley for production of flavor-stable beverage | Carlsberg A/S (DK) | 2011-03-02 | — | — | EP | claimed |
| US-7838053-B2 | Barley for production of flavor-stable beverage | CARLSBERG A/S (DK) | 2010-11-23 | — | — | US | claimed |
| US-20090029000-A1 | Barley for Production of Flavor-Stable Beverage | CARLSBERG A/S (DK) | 2009-01-29 | — | — | US | claimed |
| CN-1981041-A | Barley for production of flavor-stable beverage | CARLSBERG AS (DK) | 2007-06-13 | — | — | CN | claimed |
| EP-1727905-A2 | BARLEY FOR PRODUCTION OF FLAVOR-STABLE BEVERAGE | Carlsberg A/S (DK) | 2006-12-06 | — | — | EP | claimed |
| WO-2005087934-A2 | BARLEY FOR PRODUCTION OF FLAVOR-STABLE BEVERAGE | CARLSBERG A/S (DK) | 2005-09-22 | — | — | WO | claimed |
| US-20050204437-A1 | Barley for production of flavor-stable beverage | CARLSBERG A/S (DK) | 2005-09-15 | — | — | US | claimed |
| US-20260041696-A1 | IN-SITU PRODUCTION OF ANTI-INFLAMMATORY LIPIDS USING MILK FAT GLOBULES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-02-12 | — | — | US | disclosed |
| US-12479812-B2 | Fatty acid derivatives and their use | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2025-11-25 | — | — | US | disclosed |
| EP-4468884-A1 | LYMPH-RELEASING COMPOSITIONS OF FATTY ACIDS AND USES THEREOF FOR LYMPHATIC INCORPORATION AND SYSTEMIC DISEASE TREATMENT | Amarin Pharmaceuticals Ireland Limited (IE) | 2024-12-04 | — | — | EP | disclosed |
| EP-1727905-A2 | BARLEY FOR PRODUCTION OF FLAVOR-STABLE BEVERAGE | Carlsberg A/S (DK) | 2006-12-06 | — | — | EP | disclosed |
| WO-2005087934-A2 | BARLEY FOR PRODUCTION OF FLAVOR-STABLE BEVERAGE | CARLSBERG A/S (DK) | 2005-09-22 | — | — | WO | disclosed |
| US-20050204437-A1 | Barley for production of flavor-stable beverage | CARLSBERG A/S (DK) | 2005-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260041696-A1 | IN-SITU PRODUCTION OF ANTI-INFLAMMATORY LIPIDS USING MILK FAT GLOBULES | ALOX5, ALOX15, ALOX15B | FFAR1 222/4885FFAR4 172/4885PTPN1 4301/4885 |
| US-12479812-B2 | Fatty acid derivatives and their use | FFAR3, FFAR1, FFAR2 | FFAR1 2/4885FFAR4 4/4885PTPN1 2179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.